Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study

BACKGROUND: Few studies on the long-term efficacy of benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, have been conducted for patients with severe eosinophilic asthma (SEA), especially regarding the improvement of pulmonary function and clinical remission in a real-world setting....

Descripción completa

Detalles Bibliográficos
Autores principales: Numata, Takanori, Araya, Jun, Okuda, Keitaro, Miyagawa, Hanae, Minagawa, Shunsuke, Ishikawa, Takeo, Hara, Hiromichi, Kuwano, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719274/
https://www.ncbi.nlm.nih.gov/pubmed/36471877
http://dx.doi.org/10.2147/JAA.S391807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719274/
https://www.ncbi.nlm.nih.gov/pubmed/36471877
http://dx.doi.org/10.2147/JAA.S391807

Ejemplares similares